

Flerie's portfolio company Xspray Pharma has raised SEK 161 million in oversubscribed rights issue

Stockholm, Sweden, September 11, 2025. Flerie AB's (publ) portfolio company Xspray Pharma has announced that the company has raised SEK 161 million before transaction costs in an oversubscribed rights issue. The company reports that the rights issue was fully subscribed, with subscriptions corresponding to approximately 245 per cent of the shares offered.

The financing will support the launch of Dasynoc in the U.S. market, advance the FDA process, and prepare for the commercialisation of XS003-nilotinib. The funds will also strengthen the company's project portfolio and secure financing until an expected positive cash flow in the second half of 2026.

"We are glad to see that Xspray Pharma attracted such strong interest from both existing and new investors. This demonstrates the market's confidence in the company's strategy and long-term potential," says Ted Fjällman, CEO of Flerie.

Flerie subscribed for its pro rata share in the rights issue, and its holding in Xspray Pharma amounts to 18%.

Read Xspray Pharma's full press release here:

<https://mf.n.se/a/xspray-pharma/xsprays-rights-issue-oversubscribed-over-allotment-issue-increased-and-fully-utilized>

For more information:

Ted Fjällman, CEO

Email: ir@flerie.com

Flerie in brief

Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie's active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB's ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com

Attachments

[Flerie's portfolio company Xspray Pharma has raised SEK 161 million in oversubscribed rights issue](#)